JNJ

Johnson & Johnson (JNJ) is the lead sponsor of 192 active clinical trials listed on ClinicalTrials.gov^[5], including 78 Phase 3^[1], 52 Phase 2^[2], 53 Phase 1^[3], 5 Phase 4^[4].

Trial NCT07217587^[6] evaluates Nipocalimab in Myasthenia Gravis with a target enrollment of 115 participants. Trial NCT00980538^[7] evaluates Etravirine in HIV Infections with a target enrollment of 180 participants. Trial NCT05528510^[8] evaluates Guselkumab Dose 1 in Colitis, Ulcerative with a target enrollment of 418 participants.

JNJ has 3 Form 4 insider filings recorded at the SEC in the past 30 days^[9].